Back to Search
JOHN HEYMACH, M.D.
M.D.
Medical Oncology Physician
NPI: 1417056565IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
M2645(TX)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
M2645(TX)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
STANFORD UNIVERSITY SCHOOL OF MEDICINE
Class of 1998
Research & Publications (20)
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
PMID 16857825·Clin Cancer Res·2006
6-review
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
PMID 19447865·Clin Cancer Res·2009
7-preclinical
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
PMID 19244104·Cancer Res·2009
8-other
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
PMID 19447868·Clin Cancer Res·2009
8-other
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
PMID 19662677·J Clin Invest·2009
7-preclinical
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
PMID 19402074·Cancer·2009
6-review
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
PMID 19118054·Clin Cancer Res·2009
4-observational
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
PMID 18451246·Clin Cancer Res·2008
7-preclinical
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
PMID 18520296·J Thorac Oncol·2008
6-review
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.
PMID 18245671·Mol Cancer Ther·2008
7-preclinical
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
PMID 18440031·Microvasc Res·2008
7-preclinical
Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.
PMID 18374947·J Surg Res·2008
7-preclinical
Second-line treatment of advanced non-small cell lung cancer.
PMID 18379366·J Thorac Oncol·2008
3-trial
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
PMID 18381602·J Cell Physiol·2008
7-preclinical
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
PMID 18936474·J Clin Oncol·2008
3-trial
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
PMID 19029832·Cell Cycle·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1417056565
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile